TABLE 4.
REID [Radiation-Induced Deaths/Gy (×102)] (95% BCI) at Test Dose of 0.1 Gy Weighted Dose for Various Populations and Risk Transfer Methods (Excess Relative Rate, Excess Absolute Rate), Both Sexesa
| Mortality end point | Country (and year) | REID/Gy (×102) (95% BCI) relative rate models |
REID/Gy (×102) (95% BCI) absolute rate models |
|---|---|---|---|
| All solid cancer | UK (2017) | 3.88 (1.17, 6.97) | 3.56 (0.54, 6.78) |
| France (2014) | 3.65 (1.11, 6.58) | 4.43 (0.67, 8.55) | |
| USA (2015) | 3.84 (1.18, 6.77) | 2.89 (0.45, 5.43) | |
| Russia (2013) | 3.01 (0.92, 5.26) | 2.61 (0.41, 4.86) | |
| Japan (2015) | 3.51 (1.04, 6.40) | 4.26 (0.65, 8.18) | |
| China (2000) | 3.25 (0.98, 5.72) | 2.72 (0.42, 5.12) | |
| Lung cancer | UK (2017) | 2.61 (0.55, 5.02) | 1.65 (−0.17, 4.03) |
| France (2014) | 1.90 (0.40, 3.68) | 2.66 (−0.26, 6.85) | |
| USA (2015) | 3.10 (0.68, 5.86) | 1.22 (−0.13, 2.84) | |
| Russia (2013) | 1.03 (0.21, 2.05) | 1.09 (−0.11, 2.51) | |
| Japan (2015) | 2.08 (0.40, 4.22) | 2.25 (−0.23, 5.51) | |
| China (2000) | 2.17 (0.47, 4.10) | 1.13 (−0.12, 2.68) | |
| Stomach cancer | UK (2017) | 0.09 (−0.01, 0.26) | 0.58 (−0.23, 1.45) |
| France (2014) | 0.10 (−0.01, 0.31) | 0.71 (−0.29, 1.88) | |
| USA (2015) | 0.07 (−0.01, 0.19) | 0.51 (−0.20, 1.27) | |
| Russia (2013) | 0.31 (−0.03, 0.84) | 0.50 (−0.20, 1.22) | |
| Japan (2015) | 0.41 (−0.04, 1.26) | 0.70 (−0.29, 1.82) | |
| China (2000) | 0.44 (−0.04, 1.17) | 0.47 (−0.19, 1.16) | |
| Breast cancer | UK (2017) | 2.01 (0.53, 4.80) | 0.90 (0.32, 1.73) |
| France (2014) | 2.31 (0.56, 5.74) | 1.17 (0.39, 2.50) | |
| USA (2015) | 1.98 (0.56, 4.33) | 0.79 (0.29, 1.47) | |
| Russia (2013) | 1.60 (0.49, 3.28) | 0.77 (0.28, 1.40) | |
| Japan (2015) | 1.03 (0.30, 2.27) | 1.14 (0.39, 2.33) | |
| China (2000) | 0.53 (0.17, 1.06) | 0.72 (0.27, 1.30) | |
| All solid cancer excluding lung, stomach, breast | UK (2017) | 0.48 (−1.17, 2.38) | −0.13 (−2.21, 2.21) |
| France (2014) | 0.46 (−1.12, 2.28) | −0.15 (−2.69, 2.74) | |
| USA (2015) | 0.46 (−1.13, 2.25) | −0.11 (−1.76, 1.76) | |
| Russia (2013) | 0.40 (−1.00, 1.96) | −0.10 (−1.58, 1.56) | |
| Japan (2015) | 0.40 (−0.99, 2.01) | −0.15 (−2.58, 2.62) | |
| China (2000) | 0.39 (−0.97, 1.90) | −0.10 (−1.69, 1.68) | |
| Leukemia excluding CLL | UK (2017) | 0.35 (−0.03, 0.78) | 0.41 (0.01, 0.86) |
| France (2014) | 0.46 (−0.04, 0.99) | 0.41 (0.01, 0.87) | |
| USA (2015) | 0.44 (−0.03, 0.97) | 0.39 (0.01, 0.82) | |
| Russia (2013) | 0.32 (−0.02, 0.87) | 0.37 (0.01, 0.78) | |
| Japan (2015) | 0.32 (−0.02, 0.70) | 0.41 (0.01, 0.87) | |
| China (2000) | 0.36 (−0.02, 1.18) | 0.39 (0.01, 0.83) | |
| Circulatory disease | UK (2017) | 2.24 (−0.17, 13.76) | 1.56 (−1.10, 7.21) |
| France (2014) | 2.65 (−0.18, 16.63) | 2.73 (−1.93, 15.45) | |
| USA (2015) | 2.84 (−0.25, 15.91) | 1.26 (−0.92, 5.71) | |
| Russia (2013) | 5.16 (−0.53, 25.29) | 1.16 (−0.86, 5.20) | |
| Japan (2015) | 2.69 (−0.19, 16.75) | 2.34 (−1.66, 12.17) | |
| China (2000) | 3.48 (−0.34, 18.29) | 1.10 (−0.80, 4.89) |
a
For all end points a burn-in of one half the total Monte Carlo samples was used; for most end points a total of 50,000 Monte Carlo samples was used, with the exception of leukemia (250,000 for the relative rate model, 200,000 for the absolute rate model), lung cancer (75,000 for the relative rate model), breast cancer (150,000 for the relative rate model) and circulatory disease (100,000 for the relative rate model, 150,000 for the absolute rate model).